Fremanezumab for preventing migraine: Final appraisal document

DRAFT guidance recommends fremanezumab for preventing migraine in adults, only if migraine is chronic, ≥3 preventive drugs have failed and company provides it according to commercial arrangement. Treatment is stopped if migraine frequency does not reduce by≥30% after 12 weeks.

National Institute for Health and Care Excellence